REFERENCES
  1. Dhillon S. Carotegrast methyl: First approval. Drugs . 2022;82(9):1011-6. doi: 10.1007/s40265-022-01732-0.
  2. Yoshimura N, Watanabe M, Motoya S, et al. Safety and efficacy of AJM300, an oral antagonist of α4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology . 2015;149(7):1775-83.e2. doi: 10.1053/j.gastro.2015.08.044.
  3. Matsuoka K, Watanabe M, Ohmori T, et al. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Gastroenterol Hepatol . 2022;7(7):648-57. doi: 10.1016/S2468-1253(22)00022-X.
  4. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.N Engl J Med . 2012;366(20):1870-80. doi: 10.1056/NEJMoa1107829.
  5. McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry . 2016;87(2):117-25. doi: 10.1136/jnnp-2015-311100.
  6. Williamson EML, Berger JR. Diagnosis and treatment of progressive multifocal leukoencephalopathy associated with multiple sclerosis therapies. Neurotherapeutics . 2017;14(4):961-73. doi: 10.1007/s13311-017-0570-7.
  7. Package insert of Carogra® Tablets. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/111890_2399018F1024_1_02Japanese. Accessed August 20, 2023.
  8. Fukase H, Kajioka T, Oikawa I, Ikeda N, Furuie H. Food effect on a single high dose of carotegrast methyl, an oral antagonist of α4-integrin, in healthy male subjects: a randomised, placebo-controlled, double-blind study. Clin Drug Investig . 2020;40(3):237-47. doi: 10.1007/s40261-019-00879-1.
  9. Fukase H, Kajioka T, Oikawa I, Ikeda N, Furuie H. AJM300, a novel oral antagonist of α4-integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects.Br J Clin Pharmacol. 2020;86(3):591-600. doi: 10.1111/bcp.14151.
  10. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet . 2012;380(9853):1606-19. doi: 10.1016/S0140-6736(12)60150-0.
  11. Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc . 2014;89(11):1553-63. doi: 10.1016/j.mayocp.2014.07.002.
  12. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet . 2017;389(10080):1756-70. doi: 10.1016/S0140-6736(16)32126-2.
  13. Nigam SK. What do drug transporters really do? Nat Rev Drug Discov . 2015;14(1):29-44. doi: 10.1038/nrd4461.
  14. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol . 2009;158(3):693-705. doi: 10.1111/j.1476-5381.2009.00430.x.
  15. Ministry of Health, Labour and Welfare, Guideline on drug interaction for drug development and appropriate provision of information. https://www.pmda.go.jp/files/000228122.pdf. Accessed April 8, 2023.
  16. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther . 1997;62(3):248-60. doi: 10.1016/S0009-9236(97)90027-8.
  17. Kambayashi R, Goto A, Izumi-Nakaseko H, et al. Appraisal of ICH E14/S7B Q&As adopted in February 2022 using thorough QT/QTc study data for α4-integrin antagonist carotegrast methyl in Japanese healthy subjects. J Pharmacol Sci . 2022;150(3):191-9. doi: 10.1016/j.jphs.2022.08.007.
  18. The package insert of Rifampicin Capsules. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/430574_6164001M1216_1_15. Japanese. Accessed 18 June, 2023.
  19. Shumaker RC, Aluri J, Fan J, Martinez G, Thompson GA, Ren M. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.Clin Drug Investig . 2014;34(9):651-9. doi: 10.1007/s40261-014-0217-y.
  20. Agarwal SK, Hu B, Chien D, Wong SL, Salem AH. Evaluation of rifampin’s transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a BCL-2 inhibitor: results of a single- and multiple-dose study. J Clin Pharmacol . 2016;56(11):1335-43. doi: 10.1002/jcph.730.